Similar articles for PMID: 30194193

Year	Number of Results
1997	1
2002	1
2003	1
2007	1
2008	5
2009	2
2010	2
2011	7
2012	12
2013	23
2014	26
2015	31
2016	30
2017	35
2018	36
2019	35
2020	34
2021	16
2022	8
2023	3
2024	0

1

Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma.

Ueda K, Suekane S, Hirano T, Ogasawara N, Chikui K, Uemura K, Nakiri M, Nishihara K, Matsuo M, Igawa T. Ueda K, et al. Anticancer Res. 2018 Sep;38(9):5387-5392. doi: 10.21873/anticanres.12868. Anticancer Res. 2018. PMID: 30194193

2

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Motzer RJ, et al. Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16. Lancet Oncol. 2013. PMID: 23598172 Clinical Trial.

3

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.

Johnson AC, Matias M, Boyle H, Escudier B, Molinier A, Laguerre B, Helissey C, Brachet PE, Dugué AE, Mourey L, Coquan E, Joly F. Johnson AC, et al. BMC Cancer. 2017 May 22;17(1):355. doi: 10.1186/s12885-017-3312-7. BMC Cancer. 2017. PMID: 28532444 Free PMC article.

4

Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.

Umeyama Y, Shibasaki Y, Akaza H. Umeyama Y, et al. Future Oncol. 2017 Sep;13(21):1839-1852. doi: 10.2217/fon-2017-0104. Epub 2017 Jul 14. Future Oncol. 2017. PMID: 28707479 Review.

5

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.

Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI. Escudier B, et al. Br J Cancer. 2014 Jun 10;110(12):2821-8. doi: 10.1038/bjc.2014.244. Epub 2014 May 13. Br J Cancer. 2014. PMID: 24823696 Free PMC article. Clinical Trial.

6

Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.

Matias M, Le Teuff G, Albiges L, Guida A, Brard C, Bacciarelo G, Loriot Y, Massard C, Lassau N, Fizazi K, Escudier B. Matias M, et al. Eur J Cancer. 2017 Jul;79:185-192. doi: 10.1016/j.ejca.2017.04.015. Epub 2017 May 13. Eur J Cancer. 2017. PMID: 28511146

7

Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.

Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, Choueiri TK, Heng DYC. Davis ID, et al. Eur Urol. 2017 Jun;71(6):970-978. doi: 10.1016/j.eururo.2016.09.047. Epub 2016 Oct 19. Eur Urol. 2017. PMID: 27771126

8

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.

Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, Rosbrook B, Chen C, Kim S, Vogelzang NJ. Hutson TE, et al. Lancet Oncol. 2013 Dec;14(13):1287-94. doi: 10.1016/S1470-2045(13)70465-0. Epub 2013 Oct 25. Lancet Oncol. 2013. PMID: 24206640 Clinical Trial.

9

Axitinib for the treatment of advanced renal cell carcinoma.

Akaza H, Fukuyama T. Akaza H, et al. Expert Opin Pharmacother. 2014 Feb;15(2):283-97. doi: 10.1517/14656566.2014.868436. Epub 2013 Dec 13. Expert Opin Pharmacother. 2014. PMID: 24328549 Review.

10

Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan.

Miyake H, Harada KI, Ozono S, Fujisawa M. Miyake H, et al. Clin Genitourin Cancer. 2017 Feb;15(1):122-128. doi: 10.1016/j.clgc.2016.06.019. Epub 2016 Jul 5. Clin Genitourin Cancer. 2017. PMID: 27473522

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

258 results

Results by year